logo
Book a meeting
Cogentis Therapeutics

Cogentis Therapeutics

Biotechnology, 3717 Boston St, Baltimore, Maryland, 21224, United States, 1-10 Employees

cogentistherapeutics.com

  • LinkedIn

phone no Phone Number: 44********

Who is COGENTIS THERAPEUTICS

Cogentis Therapeutics is an early stage biotechnology company with a mission to develop and commercialize an innovative disease-modifying therapeutic for dementias such as frontotemporal ...

Read More

lock icon Get Full Access
map
  • 3717 Boston St, Baltimore, Maryland, 21224, United States Headquarters: 3717 Boston St, Baltimore, Maryland, 21224, United States
  • 2015 Date Founded: 2015
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731

checked-icon Does something look wrong? Fix it. | View contact records from COGENTIS THERAPEUTICS

Cogentis Therapeutics Org Chart and Mapping

Employees
Albert Hunt

Albert Hunt

Director of Scientific Operations

See Full Org Chart arrow
email-formate-icon
View Email Formats for Cogentis Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Cogentis Therapeutics

Answer: Cogentis Therapeutics's headquarters are located at 3717 Boston St, Baltimore, Maryland, 21224, United States

Answer: Cogentis Therapeutics's phone number is 44********

Answer: Cogentis Therapeutics's official website is https://cogentistherapeutics.com

Answer: Cogentis Therapeutics's revenue is Under $1 Million

Answer: Cogentis Therapeutics's SIC: 8731

Answer: Cogentis Therapeutics has 1-10 employees

Answer: Cogentis Therapeutics is in Biotechnology

Answer: Cogentis Therapeutics contact info: Phone number: 44******** Website: https://cogentistherapeutics.com

Answer: Cogentis Therapeutics is an early stage biotechnology company with a mission to develop and commercialize an innovative disease-modifying therapeutic for dementias such as frontotemporal dementia (FTD) and Alzheimers disease (AD) to improve patients quality of life and reduce the burden of disease on their families, providers, and the overall healthcare system. Our immediate goal is to develop a peptide-based compound, CT-526, for FTD.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access